Newly-Approved Drug for HR+, HER2- PI... - SHARE Metastatic ...

SHARE Metastatic Breast Cancer

6,598 members8,139 posts

Newly-Approved Drug for HR+, HER2- PI3K Mutant MBC

Bestbird profile image
7 Replies

Some good news about a therapy that was just approved in the US (hopefully other countries to follow!)

The PI3K (or PIK3CA) mutation is frequently found in metastatic breast cancer tumors, and it can be diagnosed via a liquid biopsy or a tumor biopsy.

Until recently, there has not been an approved therapy targeting this mutation. The good news is that Alpelisib, an oral PI3K inhibitor, was FDA-approved in May 2019 for the treatment of postmenopausal women (and men) with HR-positive, HER2-negative, PIK3CA-mutated MBC following progression on or after a hormonal therapy regimen.

Alpelisib's approval was based upon the SOLAR-1 Phase 3 clinical trial which compared Faslodex plus Alpelisib versus Faslodex plus placebo in postmenopausal patients with PIK3CA mutations that were found via liquid or tumor biopsy. Patients in the Faslodex/Alpelisib arm fared substantially better (median PFS 11.0 months) than similar patients in the Faslodex plus placebo arm (median PFS 5.7 months). Patients in this trial had received 1 or more lines of prior hormonal therapy but no chemotherapy. The Overall Response Rate in the PIK3CA-mutant group was 26.6% in the Faslodex/Alpelisib arm compared with 12.8% in the Faslodex/placebo group. These results, assessed after a median follow-up of 20 months, translated into a 35% reduction in the risk of progression or death in favor of Faslodex/Alpelisib arm. (There was no advantage to providing Alpelisib in patients without a PIK3CA mutation).

The FDA has also approved the companion diagnostic test “Therascreen PIK3CA RGQ PCR Kit” to detect the PIK3CA mutation in a tissue and/or a liquid biopsy. Patients whose results are negative by the Therascreen test using the liquid biopsy are encouraged to undergo tumor biopsy for PIK3CA mutation testing. From: targetedonc.com/news/alpeli... and fda.gov/news-events/press-a...

As an aside, this and other information can be found in my book, "The Insider's Guide to Metastatic Breast Cancer" which is also available in a complimentary .pdf. For more information, please visit: insidersguidembc.com/about

With good wishes!

Written by
Bestbird profile image
Bestbird
To view profiles and participate in discussions please or .
Read more about...
7 Replies
SoCalLady profile image
SoCalLady

Thank you for the through information. Happy Memorial Day!

Pollingxx profile image
Pollingxx

I am on a trial for the pk , so far so good

mariootsi profile image
mariootsi in reply to Pollingxx

How are side effects?

Pollingxx profile image
Pollingxx in reply to mariootsi

Nausea when I started but that has completely subsided.

My hair is a bit thin and my curl has gone .

So very good xx

mariootsi profile image
mariootsi in reply to Pollingxx

Oh good!

I just received my results from the Liquid Biopsy and I am 25-30% positive for the Pik3 mutation. I’m currently on IBrance/Faslodex/Xgeva. Questions:

1. Should I request my oncologist replace IBrance with Alpelisib?

2. Or is it better to stay on my current drugs until it stops working then change to Alpelisib?

3. Do you know what the 25-30% positive means?

Thank you,

❤️🙏❤️

Bestbird profile image
Bestbird in reply to hopenowandtomorrow

These are excellent questions to ask your oncologist!

You may also like...

A newly approved med!

this!...

Overall Survival With Palbociclib and Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer

palbociclib plus fulvestrant compared with fulvestrant alone in patients with HR+/HER2− advanced...

Good News for HER2 Positive MBC Patients!

adc16f7bae11%7D/fda-approves-tukysa-as-part-of-combination-therapy-for-breast-cancer The above and...

new MBC drug for PIK3CA mutation in Hr+HER- breast cancer survivors

16, 2023, the FDA approved another drug for those who have developed the PIK3CA. Mutation after...

Alpelisib Plus Fulvestrant in Patients With HR+, HER2− Advanced Breast Cancer

July 09, 2022 Alpelisib Plus Fulvestrant in Patients With HR+, HER2− Advanced Breast Cancer Journal...